Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

Introduction Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall effic...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2023-09, Vol.14 (9), p.1517-1535
Main Authors: Sugawara, Masahiro, Fukuda, Masahiro, Sakuma, Ichiro, Wakasa, Yutaka, Funayama, Hideaki, Kondo, Akira, Itabashi, Naoki, Maruyama, Yasuyuki, Kamiyama, Takashi, Utsunomiya, Yasunori, Yamauchi, Akira, Yoshii, Hidenori, Yamada, Hirokazu, Mochizuki, Koichi
Format: Article
Language:English
Subjects:
Antidiabetics
Body mass index
Cardiology
Comparative analysis
Diabetes
Dosage and administration
Drug therapy
Endocrinology
Hypoglycemic agents
Internal Medicine
jRCTs
jRCTs031180241
Medicine
Medicine & Public Health
Original Research
Patient outcomes
Testing
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall efficacy and safety of DPP-4is and the SGLT2i luseogliflozin in patients with type 2 diabetes mellitus (T2DM). Methods Patients with T2DM who had not used antidiabetic agents or who had used antidiabetic agents other than SGLT2is and DPP-4is were enrolled in the study after written informed consent had been obtained. The enrolled patients were subsequently randomly assigned to either the luseogliflozin or DPP-4i group and followed up for 52 weeks. The primary (composite) endpoint was the proportion of patients who showed improvement in ≥ 3 endpoints among the following five endpoints from baseline to week 52: glycated hemoglobin (HbA1c), weight, estimated glomerular filtration rate (eGFR), systolic blood pressure, and pulse rate. Results A total of 623 patients were enrolled in the study and subsequently randomized to either the luseogliflozin or DPP-4i groups. The proportion of patients who showed improvement in ≥ 3 endpoints at week 52 was significantly higher in the luseogliflozin group (58.9%) than in the DPP-4i group (35.0%) ( p  
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-023-01438-w